Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat…
$15.85+0.89%
报价 2026-11-06
市值
$2.2B
EV
$5.16B
PE (TTM)
–
预期 PE (FY2026)
6.9x
52 周区间距高点 -4.7%
$9.25$16.63
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
电话会信号
辅助标签Q3 20262026-11-04
下调/撤回指引
指引 下调
信心 3
分析师 4
“We are gaining share on both sides of the Atlantic, and e-commerce is driving further improvement.”
原文引用（1）
- 下调/撤回指引：we have updated our 2026 outlook to reflect the infant formula divestment, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - Specialty & Generic| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| PRGOPerrigo Company plc | $2.2B | +0.9% | -6.0% | 30.7% | – | – | 12.9x | |
| BHCBausch Health Companies Inc. | $3.06B | +2.8% | +7.5% | 75% | – | 8.9x | 1.7x | |
| HCMHutchison China Ltd. | $2.64B | +6.8% | +10.9% | 17% | 145.0x | – | 234.4x | |
| RGCRegencell Bioscience Holdings Limited | $2.61B | -2.8% | – | 0% | – | – | – | |
| TRLVTrulieve Cannabis Corp. | $1.97B | +6.1% | -15.1% | 59.9% | – | 6.8x | 8.2x | |
| ALVOAlvotech | $1.73B | +6.8% | +1.1% | 50.7% | – | – | – | |
| ANIPANI Pharmaceuticals, Inc. | $1.55B | -3.2% | +27.2% | 61.6% | 13.0x | 5.3x | 8.1x | Cheap GARP |
| SUPNSupernus Pharmaceuticals, Inc. | $1.52B | -2.2% | +25.9% | 85.7% | 7.1x | 3.0x | 49.1x | Cheap GARP |
| PCRXPacira BioSciences, Inc. | $1.45B | +0.0% | +3.3% | 77% | 103.2x | 14.4x | 8.1x | |
| 同行中位数 | – | – | +7.5% | 60.8% | 58.1x | 6.8x | 8.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-27 Q2 2026 | 2026-03-28 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-27 Q3 2025 | 2025-06-28 Q2 2025 | 2025-03-29 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-28 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.02B | $969.2M | $1.11B | $1.04B | $1.06B | $1.04B | $1.14B | $1.09B |
| Gross Margin | 30.7% | 33.6% | 32.6% | 36.1% | 34.4% | 37.6% | 33.9% | 37.2% |
| Operating Margin | 2.3% | 3.5% | 7.6% | 7% | 4.3% | 4.5% | 10% | 7.4% |
| Net Income | $74.5M | $-398.6M | $-1.42B | $7.5M | $-8.4M | $-6.4M | $-44.5M | $-21M |
| Diluted EPS | 0.53 | -2.87 | -10.23 | 0.05 | -0.06 | -0.05 | -0.32 | -0.15 |
| Operating Cash Flow | $138.3M | $-113.6M | $175.4M | $51.7M | $75.9M | $-64.5M | $312.6M | $42.2M |